The multiple sclerosis treatment Tysabri returned to the shelves of US chemists today.
The move followed approval from the American Food and Drug Administration which last month supported the return of the product to the market with certain conditions.
Tysabri, produced by pharmaceutical company Elan and Biogen, has also been given approval from the European Commission.
Tysabri was withdrawn in February 2005 after two patients involved in trials of the drug died from the rare brain disease PML.
READ MORE
At 11am Irish time, Elan shares were down one cent on the Dublin market at €10.60.